Cubist's sales jump 47% on Cubicin sales
The USA's Cubist Pharmaceuticals has reported a 47% jump in revenue for the full year 2008, year-on-year, driven by domestic sales of Cubicin (daptomycin).
Total turnover increased to $433.6 million from $294.6 million in 2007. This was primarily attributable to US sales of Cubicin, which increased 45% to $414.7 million versus $285.1 million. International product revenues were $7.4 million, which represents an increase of 28%. Additionally, the full-year 2008 total net turnover includes $9.4 million of service revenue relating to Cubist's exclusive agreement with Anglo-Swedish drug major AstraZeneca to sell and provide other support in the USA for Merrem IV (meropenem).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze